Tolvaptan is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L, or less marked hyponatremia with symptomatic patients unresponsive to fluid restriction), including patients with heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
GMP DMF
